Kathleen Ford Sells 1,817 Shares of Kura Oncology, Inc. (NASDAQ:KURA) Stock

Kura Oncology, Inc. (NASDAQ:KURA) COO Kathleen Ford sold 1,817 shares of Kura Oncology stock in a transaction that occurred on Tuesday, January 28th. The shares were sold at an average price of $7.87, for a total value of $14,299.79. Following the completion of the sale, the chief operating officer now directly owns 21,367 shares in the company, valued at $168,158.29. This represents a 7.84 % decrease in their position. The sale was disclosed in a filing with the SEC, which can be accessed through the SEC website.

Kathleen Ford also recently made the following trade(s):

• On Monday, November 18th, Kathleen Ford sold 526 shares of Kura Oncology stock. The shares were sold at an average price of $16.03, for a total value of $8,431.78.

Kura Oncology Trading Down 1.0 %

Kura Oncology stock opened at $7.69 on Thursday. The stock has a market cap of $598.01 million, a PE ratio of -3.26 and a beta of 0.81. The company has a current ratio of 11.47, a quick ratio of 11.47 and a debt-to-equity ratio of 0.02. The stock has a 50-day moving average price of $9.06 and a 200 day moving average price of $15.63. Kura Oncology, Inc. has a 52 week low of $6.98 and a 52 week high of $24.17.

Kura Oncology (NASDAQ:KURA) last posted its quarterly earnings data on Thursday, November 7th. The company reported ($0.63) earnings per share for the quarter, beating analysts’ consensus estimates of ($0.64) by $0.01. During the same quarter last year, the business posted ($0.50) earnings per share. Equities research analysts predict that Kura Oncology, Inc. will post -2.44 earnings per share for the current fiscal year.

Analyst Ratings Changes

Several research firms have issued reports on KURA. TD Cowen reiterated a “buy” rating on shares of Kura Oncology in a research report on Thursday, November 21st. StockNews.com downgraded shares of Kura Oncology from a “hold” rating to a “sell” rating in a report on Wednesday, November 20th. Cantor Fitzgerald reaffirmed an “overweight” rating on shares of Kura Oncology in a report on Monday, December 9th. Jefferies Financial Group decreased their price target on Kura Oncology from $32.00 to $28.00 and set a “buy” rating on the stock in a research note on Thursday, November 21st. Finally, Wedbush reaffirmed an “outperform” rating and issued a $37.00 price objective on shares of Kura Oncology in a research note on Monday, November 4th. One investment analyst has rated the stock with a sell rating, two have issued a hold rating, eight have assigned a buy rating and one has issued a strong buy rating to the company’s stock. According to data from MarketBeat.com, Kura Oncology has a consensus rating of “Moderate Buy” and an average target price of $27.38.

Institutional Inflows and Outflows

Several institutional investors have recently bought and sold shares of KURA. Suvretta Capital Management LLC lifted its holdings in shares of Kura Oncology by 8.2% during the 3rd quarter. Suvretta Capital Management LLC now owns 7,652,782 shares of the company’s stock worth $149,535,000 after acquiring an additional 583,155 shares during the period. Alethea Capital Management LLC raised its stake in Kura Oncology by 108.2% during the third quarter. Alethea Capital Management LLC now owns 553,542 shares of the company’s stock worth $10,816,000 after purchasing an additional 287,636 shares during the period. Point72 Asset Management L.P. acquired a new position in shares of Kura Oncology in the 3rd quarter valued at $3,695,000. Barclays PLC boosted its holdings in Kura Oncology by 104.5% in the third quarter. Barclays PLC now owns 165,484 shares of the company’s stock valued at $3,234,000 after acquiring an additional 84,563 shares during the last quarter. Finally, Jennison Associates LLC purchased a new stake in Kura Oncology during the fourth quarter valued at about $623,000.

Kura Oncology Company Profile

Kura Oncology, Inc, a clinical-stage biopharmaceutical company, develops medicines for the treatment of cancer. The company’s pipeline consists of small molecule product candidates that target cancer. Its lead product candidates are ziftomenib, an orally bioavailable small molecule inhibitor of the menin-KMT2A interaction for the treatment of genetically defined subsets of acute leukemias, including acute myeloid leukemia and acute lymphoblastic leukemia; tipifarnib, an orally bioavailable farnesyl transferase inhibitor combination with alpelisib for patients with PIK3CA-dependent HNSCC; and KO-2806, a farnesyl transferase inhibitor for the treatment of solid tumors.